

PERSONAL INFORMATION **Ilaria Pellegrini**

WORK EXPERIENCE

- 20/01/2020–28/12/2022 **Medical Oncology Resident**
 Istituto Nazionale Dei Tumori, Milan (Italy)
 Gained experience in the sarcoma department by working full-time with inward and outward sarcoma patients with a specific interest in soft tissue sarcomas and desmoid tumours.
 I conducted a retrospective case-series analysis on intra-abdominal desmoid tumours comparing different types of systemic therapies normally used to treat this rare disease.
 I'm taking part on a project on breast angiosarcomas aiming to write an updated national consensus.
- 29/12/2017–29/12/2019 **Medical Oncology Resident**
 Policlinico Santa Maria alle Scotte, Siena (Italy)
- 03/2016–10/2016 **Medical Laboratory Assistant**
 Nanomedicine Laboratory Department of Biomedical and Clinical Science Luigi Sacco, Milano (Italy)

EDUCATION AND TRAINING

- 11/01/2013 **Certified Board Medical Oncologist (70/70 cum laude)**
 Università Degli Studi, Milan (Italy)
- 06/2022-12/2022 **EURACAN Fellowship**
 The Netherland Cancer Institute, Amsterdam (The Netherlands)
 I worked within the sarcoma and Adolescents and Young Adults research group finalising a paper on fear of cancer recurrence in sarcoma survivors.
 I actively participated to surgeons and oncologist outward clinics to understand the differences both organisational and clinic between The Netherlands and Italy
 I followed once a week the sarcoma multidisciplinary board.
- 02/2017 **Italian Examination of Qualification to Practice Medicine**
 Università Degli Studi, Milan (Italy)
- 24/10/2016 **M.D. (110/110 cum laude)**
 Università Degli Studi, Milan (Italy)
- 02/2014–07/2014 **Visiting Scholar through the Erasmus Exchange Program**
 Nicolò Copernico University - Collegium Medicum Bydgoszcz, Bydgoszcz (Poland)

PERSONAL SKILLS

Mother tongue(s) Italian

Foreign language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1	C2	C1	C1	C1

Curriculum vitae

Levels: A1 and A2: Basic user - B1 and B2: Independent user - C1 and C2: Proficient user
Common European Framework of Reference for Languages - Self-assessment grid

Communication skills Good contact skills with foreigners people gained during my Erasmus Exchange Program in Poland, my English Language course in South Africa and my observership in The Netherlands.

Organisational / managerial skills Good organisational skills gained as children education volunteer

ADDITIONAL INFORMATION

Certifications During Investigator Meetings attended, I received training on GCP (4 March 2020).

Courses 1 month English Course in August 2011 at LAL school in Cape Town (South Africa)

Courses Adults and Pediatric BLSD

Courses 3 modules course + 2 days meeting on chronic pain management

Courses ESMO Breast Cancer Virtual Meeting 2020

Courses Esmo preceptorship on Molecular Cancer Biology for practising oncologist
and cancer treatment de-escalation 2021

Publications

Articles

- *“Fear of Cancer Recurrence in Sarcoma Survivors: Results from the SURVSARC Study.”* Pellegrini I, Drabbe C, Grünhagen DJ, Van de Sande MAJ, de Haan JJ, Keymeulen KBMI, Bonenkamp JJ, Van der Graaf WTA, Husson O. *Cancers (Basel)*. 2022 Dec 11;14(24):6099. doi: 10.3390/cancers14246099. PMID: 36551585
- *“NR4A3 fusion molecular profile change pathological diagnosis? A case report.”* Pellegrini I, Quattrone P, Dagrada G, Vischioni B, Orlandi E, Colombo E, Licitra L, Locati LD. *Oral Oncol*. 2022
- *“Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer”.* Ligorio F, Pellegrini I, Castagnoli L, Vingiani A, Lobefaro R, Zattarin E, Santamaria M, Pupa SM, Pruneri G, de Braud F, Vernieri C. *Cancer Lett*. 2021 Jul 28

Abstract and Posters

- *“A retrospective case series analysis of 22 rhabdomyosarcoma patients with spindle-cell/sclerosing morphology”* Provenzano S., Crippa N., Apollonio G., Pellegrini I., Brotea-Mosoiu S., Collini P., Barisella M., Tamborini E., Radaelli S., Callegaro D., Guzzo M., Sangalli C., Allajbej A., Morosi C., Ferrari A., Bertulli R., Casali P.G. CTOS 2022
- *“Toxicity profiles in a real-world cohort of head and neck cancer patients treated with nivolumab 240 mg every 14 days and/or 480 mg every 28 days during the COVID-19 pandemic”* Elena Colombo, Stefano Cavalieri, Francesca Caspani, Margherita Ambrosini, Giuseppe Fotia, Rita Leporati, Ilaria Pellegrini, Chiara C. Pircher, Laura D. Locati, Cristiana Bergamini, Roberta Lombardo, Imperia Nuzzolese, Laura Frisardi, Irene Parasole, Lisa Licitra, Carlo Resteghini. AIOM 2021
- *“Phase II study of preoperative (PREOP) chemoradiotherapy (CRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study”.* Salvatore L, Bensi M, Corallo S, Bergamo F, Pellegrini I, Rasola C, Borelli B, Tamburini E, Randon G, Galuppo S, Boccaccino A, Viola MG, Auriemma A, Fea E, Barbara C, Bustreo S, Smirolto V, Barbaro B, Gambacorta MA, Tortora G. ASCO 2021

I hereby certify that this document is an accurate representation of my qualifications.

I consent for the use of my personal data according to the Italian Privacy laws (DL 196/03)